By the end of this video, you'll be able to define
plasma protein binding, PPB. You will also be able to
list the proteins that are most responsible for PPB. Finally, you will
be able to describe the importance of measuring PPB. Plasma protein binding or PPB is one of the
key PK parameters. PPB is the degree to which a drug is bound to proteins
present in the blood. Plasma is the protein rich
fraction of the blood, and hence, it is
used to determine the extent of drug
protein binding. The protein content
of plasma is around 60-80 milligram per milliliter. Approximately 60% of
the protein is albumin. Albumin tends to bind
acidic and neutral drugs. Approximately 3% is
Alpha-1 acid glycoprotein, which tends to bind basic drugs. There are many other
plasma proteins, but these two are among the most important for drug binding. There are many reasons
for understanding PPB. The free drug hypothesis
states that at steady state, the concentration
of unbound drug in plasma is the same as that
at the site of action. PPB affects drug disposition as only unbound drug
can cross membranes. Most clearance mechanisms
only affect unbound drug. PPB can vary across different pre-clinical
species and can even be influenced by the disease
state of a patient. Therefore, a thorough
understanding of a compound's PPB can improve the accuracy of
dose predictions, and help evaluate safety risks. The commonly utilized
techniques for determining plasma
protein binding are, equilibrium dialysis, ultrafiltration, and
ultracentrifugation. Measuring plasma protein
binding gives us the fraction of drug that
is unbound in plasma. The unbound or free fraction
is represented as f_u. C_p is total plasma
concentration, and includes the
concentrations of both the bound and unbound drug. The concentration
of unbound drug is calculated as the product of the total drug concentration
and the unbound fraction, that is C_p unbound= C_p, that is C_p total × f_u. Unbound fraction is a key
pharmacokinetic parameter. There is no ideal value
for unbound fraction. Safe effective drugs with high and low unbound
fraction values, even less than 1% unbound exist. Therefore, PPB is rarely a factor in choosing
a drug candidate. Understanding PPB
however, is critical for predicting dosing and
assessing safety risks. On this slide are
examples that illustrate factors that can influence PPB. First, cross-species
differences in PPB. Cefpiramide is an antibiotic, and it typically has an
unbound fraction of 0.016, 1.6% in humans, and 0.6 in dogs. That is a 40-fold difference. Assuming similar PPB between
pre-clinical species and human may result in over or underestimation
of several factors, including the
relationship between the PK of a drug and
its pharmacodynamics, the anticipated human dose
or the safety margins. Hence, it is important
to account for species differences in PPB. For most drugs, PPB is constant across a range of clinically
relevant concentrations. However, for some drugs, high plasma concentration
can result in saturation of binding sites of the
plasma protein and consequently increasing
unbound fraction. Disopyramide, an
antiarrhythmic drug is an example of a drug that shows concentration
dependent PPB. At low concentrations, the unbound fraction
is about 0.1, so 90% of the drug is bound. At high concentrations, the unbound fraction
may be as high as 0.5. Other factors that
can contribute to differences in PPB include age, sex, pregnancy,
fed fasted state, diet, blood pH,
blood lipid profile, renal and hepatic impairment, and other disease states such
as inflammation or cancer. These are important
considerations for the drug hunting team to characterize once a candidate
drug is in the clinic. We have now covered
plasma protein binding. The unbound fraction
of a drug in plasma is a key pharmacokinetic
parameter that must be well understood
to facilitate accurate dose and safety
margin predictions.